Matthew Perry Death Investigation — Ketamine Distribution Network

The Case

The Matthew Perry death investigation is a United States federal criminal case centered on the unlawful distribution of ketamine to the Friends actor in the weeks before his fatal overdose on October 28, 2023. Federal prosecutors in the Central District of California identified an underground supply network and charged five defendants, including two doctors, with several quickly entering guilty pleas. Although the death itself was ruled an accident by the Los Angeles County Medical Examiner, the criminal case treats Perry's death as the foreseeable result of an organized drug-distribution scheme.

The Crime

On the afternoon of October 28, 2023, Matthew Perry was found unresponsive in the pool at his home in Pacific Palisades, Los Angeles. According to the official Medical Examiner notice, the cause of death was the acute effects of ketamine, with drowning, coronary artery disease and the effects of buprenorphine listed as contributing factors. The manner of death was determined to be accidental, and the autopsy was completed on October 29, 2023.

Federal investigators concluded that Perry — who had a documented history of addiction and was being treated with low-dose ketamine therapy — sought additional, unprescribed ketamine outside his legitimate medical care. Prosecutors allege that a network of suppliers exploited his addiction, charging inflated prices and providing increasing quantities of the dissociative anesthetic in the weeks leading up to his death. The superseding indictment specifically alleges that ketamine distributed by Jasveen Sangha on October 24, 2023 caused Perry's death four days later.

The Victims

Matthew Langford Perry was 54 years old at the time of his death. He was internationally famous for portraying Chandler Bing on the NBC sitcom Friends and had spoken publicly and in his memoir about his decades-long struggles with addiction. Court filings depict him as a vulnerable patient targeted by people who knew of his dependency. In messages cited by prosecutors, one of the charged doctors allegedly referred to Perry as a "moron" who could be charged exorbitant sums for the drug.

Investigation

The federal probe was conducted jointly by the Drug Enforcement Administration, the Los Angeles Police Department and the U.S. Postal Inspection Service, coordinated by the U.S. Attorney's Office for the Central District of California. Investigators traced the ketamine back through a chain that began with street-level dealer Jasveen Sangha — described by the DOJ as a San Fernando Valley source known as "The Ketamine Queen" — and ran through licensed physicians who allegedly diverted the drug for cash.

Dr. Salvador Plasencia, known as "Dr. P," was accused of obtaining ketamine from fellow physician Dr. Mark Chavez and reselling it to Perry through intermediaries. Erik Fleming acted as a broker, and Kenneth Iwamasa — Perry's live-in personal assistant — admitted he personally administered the injections, including on the day Perry died. Evidence included text messages, financial records, and the toxicology findings from the autopsy.

Trial and Verdict

When the federal charges were announced in August 2024, three defendants had already agreed to plead guilty. Kenneth Iwamasa pleaded guilty to conspiracy to distribute ketamine causing death, admitting he administered the fatal doses. Erik Fleming pleaded guilty to distribution of ketamine resulting in death. Dr. Mark Chavez pleaded guilty to conspiracy to distribute ketamine, admitting he supplied Plasencia.

The two remaining defendants — Dr. Salvador Plasencia and Jasveen Sangha — were the focus of continuing federal proceedings after the initial charging phase. Plasencia faced charges including distribution of ketamine and falsification of records, while Sangha faced the most serious counts as the alleged source of the fatal dose. The case has been extensively documented in court filings and DOJ statements detailing the network's operations.

Today

The Matthew Perry death investigation is regarded as a landmark federal prosecution targeting the illegal diversion of ketamine at a time when the drug has become increasingly popular both as a psychiatric treatment and as a recreational substance. The case has drawn attention to weaknesses in oversight of off-label ketamine prescribing and to the predatory market that has grown around celebrity patients with addiction histories. Perry's family has publicly supported the prosecution, and the case continues to be cited by federal officials as a model for charging dealers and physicians whose conduct results in fatal overdoses.